{"id":1016353,"date":"2026-11-02T16:05:53","date_gmt":"2026-11-02T21:05:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vertex-reports-third-quarter-2026-financial-results\/"},"modified":"2026-11-02T16:05:53","modified_gmt":"2026-11-02T21:05:53","slug":"vertex-reports-third-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vertex-reports-third-quarter-2026-financial-results\/","title":{"rendered":"Vertex Reports Third Quarter 2026 Financial Results"},"content":{"rendered":"

<\/p>\n

Vertex Reports Third Quarter 2026 Financial Results<\/b><\/p>\n

\u2014 Achieved total revenue of $3.44 billion, a 12% increase compared to third quarter 2025 \u2014<\/i><\/p>\n

\u2014 Raising full-year revenue guidance to $13.15 billion to $13.25 billion \u2014<\/i><\/p>\n

\u2014 Established fourth commercial pillar in rare endocrine diseases with closing of Crinetics Pharmaceuticals acquisition and preparing for fifth in renal medicine with povetacicept PDUFA date on November 30th<\/sup> \u2014<\/i><\/p>\n

\u2014 R&D pipeline continues to advance with multiple additional near-term milestones \u2014<\/i><\/p>\n

BOSTON–(BUSINESS WIRE<\/a>)–
\nVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance.<\/p>\n

\n\u201cVertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition,\u201d said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. \u201cWith the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.\u201d<\/p>\n

Third Quarter 2026 Results<\/span><\/b><\/p>\n

Total revenue<\/b> increased 12% to $3.44 billion compared to the third quarter of 2025, primarily driven by the continued performance of cystic fibrosis (CF) therapies and growth from diversification into additional disease areas. In the U.S., total revenue increased 10% to $2.17 billion from continued strong CF patient demand, including from new initiations of ALYFTREK; higher realized net prices in CF versus the prior year; and contributions from CASGEVY, JOURNAVX, and PALSONIFY. Outside the U.S., total revenue increased 16% to $1.27 billion from strong CF performance across multiple geographies, including ALYFTREK uptake; increased CASGEVY infusions; and a favorable impact from foreign exchange.<\/p>\n

GAAP and non-GAAP combined R&D, Acquired IPR&D, and SG&A expenses<\/b> were $2.2 billion compared to $1.5 billion for the third quarter of 2025 and $1.5 billion compared to $1.3 billion for the third quarter of 2025, respectively. The increases were primarily due to commercial investment to support build-out of the renal franchise, led by povetacicept in IgAN; the addition of Crinetics Pharmaceuticals; and investment to support the ongoing launch of JOURNAVX in acute pain. Combined GAAP R&D, acquired IPR&D, and SG&A expenses also reflected approximately $500 million of compensation and transaction-related expenses associated with the Crinetics Pharmaceuticals acquisition.<\/p>\n

GAAP and non-GAAP effective tax rates<\/b> were 16.6% and 18.0%, respectively, compared to 16.6% and 17.6%, respectively, for the third quarter of 2025.<\/p>\n

GAAP net income<\/b> was $654 million compared to $1.1 billion for the third quarter of 2025. The year-over-year decline is primarily due to expenses related to the Crinetics Pharmaceuticals acquisition.<\/p>\n

Non-GAAP net income<\/b> was $1.2 billion in each of the third quarters of 2026 and 2025, as increased product revenue was offset by increased operating expenses to fund pipeline and commercial opportunities, as well as higher interest expense and lower interest income as a result of the Crinetics Pharmaceuticals acquisition.<\/p>\n

Cash, cash equivalents, and total marketable securities<\/b> as of September 30, 2026, were $9.8 billion, compared to $12.3 billion as of December 31, 2025, primarily due to $9.0 billion net cash used to acquire Crinetics Pharmaceuticals and to repurchase Vertex common stock pursuant to its share repurchase program, partially offset by $4.5 billion borrowed pursuant to a term loan executed in the third quarter of 2026 and cash flows provided by Vertex\u2019s operating activities.<\/p>\n

Full Year 2026 Financial Guidance<\/span><\/b><\/p>\n

\nVertex today raised its full year 2026 total revenue guidance to $13.15 billion to $13.25 billion from $13.1 billion to $13.2 billion previously. Embedded in this guidance are expectations for continued growth in CF, $500 million or more in revenue from CASGEVY and JOURNAVX combined, and $40 million to $50 million in revenue from PALSONIFY following the closing of the Crinetics Pharmaceuticals transaction on September 1. Total revenue guidance continues to reflect a year-over-year benefit of approximately 150 basis points from changes in foreign exchange rates, net of Vertex\u2019s foreign exchange hedging program. Vertex is also increasing full year 2026 combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expense guidance to reflect expenses primarily related to the operations and integration of Crinetics Pharmaceuticals for the remainder of 2026. Vertex GAAP guidance also includes approximately $500 million of compensation and transaction expenses noted above.<\/p>\n

\nVertex\u2019s financial guidance is summarized below:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0<\/p>\n<\/td>\n

\n

Current FY 2026<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

Previous FY 2026<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Total revenue<\/b><\/p>\n<\/td>\n

\n

\n$13.15 to $13.25 billion<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n$13.1 to $13.2 billion<\/p>\n<\/td>\n<\/tr>\n

\n

Legacy non-CF product revenue (CASGEVY, JOURNAVX)<\/b><\/p>\n<\/td>\n

\n

\nUnchanged<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n$0.5 billion or greater<\/p>\n<\/td>\n<\/tr>\n

\n

PALSONIFY revenue<\/b><\/p>\n<\/td>\n

\n

\n$40 to $50 million<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Combined GAAP R&D, AIPR&D, and SG&A expenses *<\/b><\/p>\n<\/td>\n

\n

\n$7.15 to $7.2 billion<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n$6.3 to $6.45 billion<\/p>\n<\/td>\n<\/tr>\n

\n

Combined non-GAAP R&D, AIPR&D, and SG&A expenses*<\/b><\/p>\n<\/td>\n

\n

\nApproximately $6.0 billion<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n$5.65 to $5.75 billion<\/p>\n<\/td>\n<\/tr>\n

\n

Non-GAAP effective tax rate<\/b><\/p>\n<\/td>\n

\n

\nUnchanged<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n19.5% to 20.5%<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n*The difference between the combined GAAP R&D, AIPR&D and SG&A expenses and the combined non-GAAP R&D, AIPR&D and SG&A expenses guidance relates primarily to $650 million to $700 million of stock-based compensation expense, and approximately $500 million of compensation and transaction costs related to the Crinetics Pharmaceuticals acquisition.<\/p>\n<\/td>\n<\/tr>\n

\n

\n**Combined GAAP and non-GAAP R&D, AIPR&D and SG&A expenses guidance includes approximately $100 million of AIPR&D expenses.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Key Business Highlights<\/span><\/b><\/p>\n

Marketed Products<\/span><\/i><\/b><\/p>\n

Cystic Fibrosis (CF) Portfolio<\/span><\/i><\/b><\/p>\n

Vertex has worked for more than 20 years to discover and develop medicines to treat the underlying cause of CF. Vertex CFTR modulators can treat approximately 95 percent of all people living with CF in core markets, including patients as young as one month old. Vertex\u2019s CF medicines are accessible in more than 65 countries across six continents. Recent highlights include:<\/i><\/p>\n